| Aug 15 |
ReShape Lifesciences GAAP EPS of -$0.06, revenue of $1.97M
|
| Aug 14 |
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
|
| Aug 13 |
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
|
| Jul 9 |
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
|
| Jul 9 |
ReShape inks all-stock merger pact with Vyome Therapeutics
|
| Jul 9 |
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
|
| May 29 |
S&P 500 Down 0.5%; Abercrombie & Fitch Earnings Top Views
|
| May 29 |
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
|
| May 18 |
ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call Transcript
|
